Clinical Trial Update: An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations. [NA]

View source ↗

Summary

An exploratory clinical study to evaluate the efficacy and safety of tunlametinib plus fruquintinib as a third-line therapy for advanced colorectal cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Tunlametinib (tunlametinib)

Snippet

Sponsor: Liu Huang | Conditions: CRC, Colorectal Cancer | NA | Status: NOT_YET_RECRUITING